Home › Leucemia mieloide acuta › Arkansas › Little Rock
Studi clinici su Leucemia mieloide acuta a Little Rock, AR
13 studi su Leucemia mieloide acuta cercano partecipanti presso sedi a Little Rock e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
In reclutamentoFase 2
- University of Arkansas for Medical Sciences, Little Rock
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- CARTI Cancer Center, Little Rock
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
In reclutamentoFase 2
- University of Arkansas for Medical Sciences, Little Rock
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
In reclutamentoFase 3
- University of Arkansas at Little Rock, Little Rock
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
In reclutamentoFase 2
- University of Arkansas for Medical Sciences, Little Rock
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
In reclutamentoFase 2
- University of Arkansas for Medical Sciences, Little Rock
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
In reclutamentoFase 2
- University of Arkansas for Medical Sciences, Little Rock
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
In reclutamentoFase 3
- Arkansas Children's Hospital, Little Rock
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
In reclutamentoFase 3
- Arkansas Children's Hospital, Little Rock
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
In reclutamentoFase 1/2
- Arkansas Children's Hospital, Little Rock
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
In reclutamentoFase 3
- Arkansas Children's Hospital, Little Rock
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
In reclutamentoStudio osservazionale
- Arkansas Children's Hospital, Little Rock
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
In reclutamentoFase 1
- Arkansas Children's Hospital, Little Rock
Studi su Leucemia mieloide acuta in altre città
- Houston, TX85 studi
- New York City, NY51 studi
- Boston, MA44 studi
- Seattle, WA41 studi
- Baldwin Park, CA40 studi
- Columbus, OH35 studi
- Philadelphia, PA34 studi
- Durham, NC33 studi
- Atlanta, GA31 studi
- Tampa, FL29 studi
- Chicago, IL26 studi
- Portland, OR25 studi
Altri studi a Little Rock
- Schizofrenia19 studi
- Cancro (tutti i tipi)14 studi
- Disturbo depressivo maggiore14 studi
- Cancro del polmone non a piccole cellule13 studi
- Obesità11 studi
- Cancro dell'endometrio10 studi
- Depressione10 studi
- Diabete di tipo 210 studi
- Cancro ai polmoni9 studi
- Malattie cardiovascolari9 studi
- Cancro della vescica9 studi
- Insufficienza cardiaca9 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.